Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (11)

2024

  1. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

  2. First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies

    Clinical Genitourinary Cancer

  3. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

    Frontiers in Oncology, Vol. 14

2023

  1. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

    Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229

2020

  1. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients

    Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2015

  1. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

    Melanoma Research, Vol. 25, Núm. 6, pp. 486-495

2014

  1. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

2008

  1. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia

    Current Medical Research and Opinion, Vol. 24, Núm. 10, pp. 2931-2942

2006

  1. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia

    Journal of the National Cancer Institute, Vol. 98, Núm. 4, pp. 273-284